We are excited to announce improvements to BiomarkerBase, increasing the coverage and analysis of literature. We’ve added biomarkers sourced only from literature, representing biomarkers in an earlier stage of development.  With this addition there are two main benefits:

  1. Access to biomarker and supporting information that is in an early stage of development (3x more biomarker coverage)
  2. Categorization of publications by supporting, contradicting, inconclusive and co-mentioned for a biomarker and disease

We are especially excited about the second benefit.  Categorizing literature as supportive or contradictory directly aligns with how researchers evaluate biomarkers for their programs.

Check out this video overview for more information.